Skip to content

User-Centric Insulin Pumps

Deadlines are 5:00 PM (Eastern). No extensions will be granted.

Milestone Date Status
Letter of Intent Required May 10, 2022 Passed
Application Jul 13, 2022 Passed
Award Notification Feb 28, 2023 Passed
Earliest Start Apr 01, 2023 Passed

Background & Purpose

Please click on the “RFA Announcement” link for complete information.


JDRF is a longstanding supporter of artificial pancreas (AP) systems, also known as automated insulin delivery (AID) or hybrid closed loop (HCL) systems. Despite demonstrated benefits of AP systems for glucose control, there are significant barriers to widespread adoption, including user burden associated with insulin pump use. JDRF invites letters of intent to develop insulin pumps with improved form factor and other “user-centric” features that improve user experience so as to enable greater adoption of pumps and AP systems.


Today there are multiple AP systems commercially available in the United States and abroad. AP systems, which are comprised of an insulin pump, a continuous glucose monitor (CGM), and a control algorithm, improve HbA1c, increase time-in-range, and reduce time spent in hypoglycemia. AP systems also have the potential to improve quality of life by reducing the burden of disease management; however, for many this benefit is stymied by the on-body burden of wearing an insulin pump, which results in some people with T1D choosing not to take advantage of AP system technology despite the proven clinical benefits. This RFA is intended to solicit projects to develop “user-centric” pumps that impose less physical and psychological burden on people with T1D as well as people with type 2 diabetes who use insulin.